2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p [q] r s t u v w x y z

Abstract Number: 142

Quality Assessment of Ultrasound Guided Synovial Biopsies Performed in Clinical Practice
Abstract Number: 1405

Quality Measures in High Priority Rheumatologic Diseases: A Systematic Literature Review and Analysis
Abstract Number: 1706

Quality of Life at Baseline in Early Psoriatic Arthritis Related to Disease Domains
Abstract Number: 1059

Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy
Abstract Number: 642

Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis
Abstract Number: 2547

Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Abstract Number: 1296

Quantitative Measurements of Cartilage, Osteophyte, and Bone Marrow Lesion Volume in Knee Osteoarthritis
Abstract Number: 3077

Quiescence in Active and Inactive Non-Infectious, Intermediate, Posterior, or Panuveitis in Patients Treated with Adalimumab

Jump to: View All • a b c d e f g h i j k l m n o p [q] r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].